Compare LEDS & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEDS | VTGN |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 10.8M |
| IPO Year | 2010 | 2014 |
| Metric | LEDS | VTGN |
|---|---|---|
| Price | $2.15 | $0.24 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $0.90 |
| AVG Volume (30 Days) | 26.2K | ★ 603.0K |
| Earning Date | 04-14-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.12 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $43,009,000.00 | N/A |
| Revenue This Year | N/A | $124.49 |
| Revenue Next Year | N/A | $353.99 |
| P/E Ratio | $107.50 | ★ N/A |
| Revenue Growth | ★ 729.81 | N/A |
| 52 Week Low | $1.01 | $0.20 |
| 52 Week High | $3.62 | $5.14 |
| Indicator | LEDS | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.94 | 41.03 |
| Support Level | $1.75 | $0.23 |
| Resistance Level | $2.17 | $0.32 |
| Average True Range (ATR) | 0.15 | 0.01 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 75.00 | 28.46 |
SemiLEDs Corp develops, manufactures, and sells light-emitting diode chips and LED components. The company's products include LED Chips, LED Components, and Lighting Products. Its products are used for general lighting applications, including street lights and commercial, industrial, system, and residential lighting; specialty industrial applications, such as ultraviolet, or Ultraviolet, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection, LED lighting for horticulture applications, architectural lighting and entertainment lighting. Substantial revenue is generated from the sale of LED components products. Geographically, it derives a majority of its revenue from Japan.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.